Novartis (VTX:NOVN) PT Set at CHF 102 by Goldman Sachs Group

Novartis (VTX:NOVN) has been assigned a CHF 102 target price by analysts at Goldman Sachs Group in a research report issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock.

A number of other brokerages also recently issued reports on NOVN. Kepler Capital Markets set a CHF 86 price objective on Novartis and gave the stock a “buy” rating in a research report on Tuesday, April 16th. UBS Group set a CHF 83 price objective on Novartis and gave the stock a “neutral” rating in a research report on Friday, May 24th. JPMorgan Chase & Co. set a CHF 85 price objective on Novartis and gave the stock a “sell” rating in a research report on Tuesday, April 9th. Jefferies Financial Group set a CHF 95 price objective on Novartis and gave the stock a “buy” rating in a research report on Thursday, April 25th. Finally, Credit Suisse Group set a CHF 88 price objective on Novartis and gave the stock a “neutral” rating in a research report on Monday, June 3rd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of CHF 89.18.

Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.



About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: Quiet Period Expirations

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.